Status:
COMPLETED
Enriched Heparin Anti COVID-19 Trial
Lead Sponsor:
UPECLIN HC FM Botucatu Unesp
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Coronavirus 19 (COVID-19) is a viral respiratory disease that was identified in December 2019 after the first cases in China, spreading rapidly until reaching pandemic status, causing the collapse of ...
Detailed Description
In view of the enormous health, financial and social crisis resulting of the pandemic caused by SARS-Cov-2, it is justified to urgently conduct tests with possible antiviral drugs. The high molecular ...
Eligibility Criteria
Inclusion
- Signature and agreement to the Free Consent Form;
- Both sexes, of any ethnic origin, aged between 18 and 90 years;
- COVID-19 infected patients diagnosed by RT-PCR (reverse-transcriptase polymerase chain reaction) or with a strong suspicion of COVID-19 by clinical evaluation through compatible clinical and radiological findings;
- Time of disease evolution less than 10 days;
- Radiological diagnosis of grade 2A pneumonia, with gas exchange ratio \> 200 on blood gas analysis (paO2 / pFiO2), characterizing mild hypoxemia;
- Indication of hospital treatment regime, provided that the period of hospitalization before inclusion is not more than 24 hours;
- Need for supplemental oxygen therapy (O2) less than 5L / min.
Exclusion
- No agreement to the terms of this study;
- Moderate or severe respiratory failure requiring admission to the ICU and the need for invasive mechanical ventilation or non-invasive ventilation (NIV) with positive pressure;
- Pregnancy or puerperium;
- Patients with hematological diseases, coagulation disorders, use of anticoagulants, previous heparin-induced allergy or thrombocytopenia, thrombocytopenia with a count of fewer than 50,000 platelets / mm3;
- COVID-19 not confirmed by RT-PCR within 72 hours of inclusion in the study.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT04743011
Start Date
June 1 2021
End Date
December 31 2021
Last Update
October 15 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
School of Medicine at Botucatu- Paulista State University- UNESP, São Paulo, Brazil
Botucatu, São Paulo, Brazil, 18607030
2
Hospital das Clinicas de Boucatu
Botucatu, São Paulo, Brazil, 18618970